Evidence map›Paper›PMID 30452595›Full record

ArticleInvestigative ophthalmology & visual science2018

Clinically Relevant Outcome Measures for the I307N Rhodopsin Mouse: A Model of Inducible Autosomal Dominant Retinitis Pigmentosa.

Michael T Massengill, Brianna Young, Deep Patel, Farwa Jafri, Ernesto Sabogal, Neil Ash, Hong Li, Cristhian J Ildefonso, Alfred S Lewin

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Forward genetic analysis using OCT screening identifiesProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Michael T MassengillDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, United States.
Brianna YoungDepartment of Ophthalmology, University of Florida College of Medicine, Gainesville, Florida, United States.
Deep PatelDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, United States.
Farwa JafriDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, United States.
Ernesto SabogalDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, United States.
Neil AshDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, United States.
Hong LiDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, United States.
Cristhian J IldefonsoDepartment of Ophthalmology, University of Florida College of Medicine, Gainesville, Florida, United States.
Alfred S LewinDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, United States.
Florida College · USUniversity of Florida · US

Funding

Development of Allele Independent Gene Therapy Strategies for Autosomal Dominant Retinitis PigmentsaF30EY027163 · NEI · UNIVERSITY OF FLORIDA · PI MASSENGILL, MICHAEL · 2016 to 2019
$177k
NEI NIH HHS F30 EY027163
6 · The paper itself

Abstract

Purpose: The I307N rhodopsin (Rho) mouse is a light-inducible model of autosomal dominant retinitis pigmentosa (adRP) that may be useful in testing therapies. We investigated the time-course of retinal changes of the I307N Rho mouse with spectral-domain optical coherence tomography (SD-OCT). Methods: SD-OCT was performed up to day 30 after light damage; electroretinography (ERG) was employed to evaluate photoreceptor function. We utilized ImageJ to analyze reflectivity of the retina. We used light and electron microscopy to assess retinal organization. We stained synaptophysin and zonula occludins-1 with immunohistochemistry to determine injury to the plexiform layers and retinal pigment epithelium (RPE). We performed lectin staining to evaluate retinal blood vessels. Results: Retinal degeneration increased with longer exposures to light. An increase in retinal thickness was detected by SD-OCT on day 1 after light challenge followed by loss of the outer nuclear layer (ONL) by day 8. Degeneration was most severe in the nasal and inferior retina. Hyper-reflectivity on SD-OCT developed as early as 1 day after light exposure. Disorganization of the ONL, condensation of photoreceptor chromatin, disruption of the outer limiting membrane, and disarray of outer segments were associated with the hyper-reflectivity. Retraction of the outer plexiform synapses and resorption of the subretinal detachment contributed to retinal thinning. The RPE remained intact, whereas atrophied major retinal vessels were evident after light damage. Conclusions: Our time-course analysis of retinal degeneration in the I307N Rho mouse with SD-OCT and other outcome measures should enable the use of the mouse model in preclinical efficacy studies and mechanistic studies.

Indexed as

Disease Models, AnimalAnimalsGenes, DominantImmunohistochemistryMicePhotoreceptor Cells, VertebrateRetinal DegenerationRetinal Ganglion CellsRetinal VesselsRetinitis PigmentosaRhodopsinSynaptophysinTomography, Optical CoherenceZonula Occludens-1 ProteinRhodopsinSynaptophysinSyp protein, mouseTjp1 protein, mouseZonula Occludens-1 Protein

Identifiers

PMID30452595
PMCPMC6237214
OpenAlexW2901085436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.